Company profile: AlzProtect
1.1 - Company Overview
Company description
- Provider of biopharmaceutical drug candidates and clinical development for neurodegenerative diseases, including Alzheimer’s disease and orphan tauopathies such as Progressive Supranuclear Palsy. Offers AZP2006 with a unique mechanism targeting amyloid toxicity, Tau phosphorylation, oxidative stress, and neuroinflammation; conducts clinical trials and partners with pharmaceutical companies for marketing.
Products and services
- Clinical Trials for Neurodegenerative Diseases: Orphan tauopathy–focused clinical programs evaluating innovative treatments in patients with Progressive Supranuclear Palsy and Alzheimer’s disease
- AZP2006: A multi-target drug candidate that mitigates amyloid peptide toxicity, reduces Tau phosphorylation, limits oxidative stress, and modulates neuroinflammation to counter neurodegeneration
- Therapeutic Strategy for Tauopathies: A pathway-targeted approach architected to curb abnormal aggregation of hyperphosphorylated Tau proteins and address neuroinflammation driving Tau-mediated neurodegeneration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AlzProtect
Torrey Pines Therapeutics
HQ: United States
Website
- Description: Provider of small molecule drug discovery and development in the United States, with a portfolio comprising candidates from proprietary drug-targeting platforms and in-licensed/acquired programs. As of August 31, 2010, the company's pipeline includes three clinical development programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Torrey Pines Therapeutics company profile →
Aspen Neuroscience
HQ: United States
Website
- Description: Provider of personalized, autologous iPSC-derived neuron replacement therapies for Parkinson’s disease. Pipeline includes ANPD001, a personalized cell therapy for sporadic Parkinson’s disease in IND-enabling studies, and ANPD002, a gene-corrected autologous neuron therapy targeting genetic variants, focusing on the GBA gene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspen Neuroscience company profile →
Canbex Therapeutics
HQ: United Kingdom
Website
- Description: Provider of treatments for spasticity in multiple sclerosis (MS) and other disorders, targeting the debilitating symptom of involuntary spasms and stiffness of limbs and torso, with a lead programme focused on improving the lives of people with this serious and incurable disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Canbex Therapeutics company profile →
Biohaven Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for neurological diseases, including rare disorders. Focuses on CGRP receptor antagonists, glutamate modulators and a myeloperoxidase inhibitor. Portfolio includes Nurtec ODT and Zavzpret for migraine, and pipeline candidates troriluzole, BHV-7000, taldefgrobep and BHV-2100 for OCD, SCA, epilepsy, bipolar disorder, SMA, obesity and neuropathic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biohaven Pharmaceuticals company profile →
Collegium Pharmaceutical
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for chronic pain, offering XTAMPZA ER (extended-release oxycodone for around-the-clock pain management), NUCYNTA ER (tapentadol for severe pain requiring daily, around-the-clock, long-term opioid treatment), NUCYNTA (tapentadol for moderate to severe acute pain in adults), BELBUCA (buprenorphine buccal film for long-term pain), and SYMPROIC (tablet for opioid-induced constipation in adults with chronic non-cancer pain).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Collegium Pharmaceutical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AlzProtect
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AlzProtect
2.2 - Growth funds investing in similar companies to AlzProtect
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AlzProtect
4.2 - Public trading comparable groups for AlzProtect
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →